Hemoglobinopathies Market: Growing Global Demand and Evolution in the Healthcare Industry, 2032

According to Nova one advisor, the global Hemoglobinopathies Market Size was valued at USD 10.1 billion in 2022 and is predicted to be worth USD 25.7 billion by 2032, with a CAGR of 13.80% from 2023 to 2032. 

Get the Free Sample Copy of Report@ https://www.novaoneadvisor.com/report/sample/7658

Key Takeaways:

• Based on type, sickle cell disease accounted for the largest share of 58.6% in 2022 and is anticipated to maintain its lead over the forecast period
• The newborn patient population with sickle cell anemia is anticipated to reach 400,000 by 2050. Half of the global sickle cell anemia burden is present in India, Nigeria, and the Democratic Republic of the Congo
• By therapy, in the thalassemia segment, the blood transfusion segment held the largest market share in 2022 and is estimated to dominate the market throughout the forecast period
• Asia Pacific is expected to witness the fastest growth over the forecast period owing to a large potential patient base and high unmet medical needs in the region
• North America held the largest market share in 2022 due to government initiatives focusing on the development of new therapies and better reimbursement scenario

Immediate Delivery Available | Buy this Premium Research Report@ https://www.novaoneadvisor.com/report/checkout/7658

Report Scope of the Hemoglobinopathies Market

Increasing awareness regarding hemoglobinopathies and government initiatives to diagnose the diseases at an early stage are expected to propel the market growth over the forecast period. Moreover, increasing R&D investment, the presence of a promising drug pipeline, and technologically advanced diagnostics platforms are expected to boost the growth of the market.

The development of novel curative technologies, such as CRISPR/Cas9 and hematopoietic stem cell transplantation, coupled with a promising pipeline, is expected to propel market growth. Moreover, the presence of regulatory agencies, such as the FDA, which are working toward improving drug approval rate by granting accelerated approval for hemoglobinopathies drugs, is expected to drive the market. For instance, in 2019, the FDA has approved four novel drugs: Reblozyl by Bristol-Myers Squibb Company, Adakveo by Novartis AG, Zynteglo by bluebird bio, Inc., and Oxbryta by Global Blood Therapeutics, Inc. for the treatment of hemoglobinopathies.

Initiatives such as the Sickle Cell Awareness Initiative (SCAI) are working toward educating the people about the disease, which will increase the diagnosis and treatment rate. SCAI also raises funds for individuals affected with sickle cell diseases (SCDs) and provides research funding. Moreover, governments of Middle Eastern and Asian countries provide funds for R&D of hemoglobinopathies treatment. For instance, various programs undertaken by governments, such as thalassemia screening in neonates and providing medicines, are impacting the market growth positively.

The high patient population in low-income countries has encouraged market players and non-profit organizations to launch several initiatives to improve the access to the therapy. For instance, in February 2019, the Access to Excellent Care for Sickle Cell Patients Pilot Program (ACCEL) was launched by Global Blood Therapeutics, Inc. in order to provide research funding for novel SCD projects, with an aim to expand the access to optimal healthcare for sickle cell disease.

Biopharmaceutical companies are collaborating with nonprofit organizations to promote public awareness about hemoglobinopathies. For instance, in June 2018, the Sickle Cell Disease Association of America partnered with Emmaus Life Sciences, Inc. to provide online educational tools to sickle cell patients, friends, clinicians, caregivers, and researchers for spreading awareness about complications associated with SCD.

An increase in investment and funding for the development of novel therapies to treat hemoglobinopathies will further boost the market growth over the forecast period. The National Heart, Lung, and Blood Institute (NHLBI) has significantly invested in research & development in sickle cell disease. The NHLBI supports research work through various initiatives. Furthermore, private funding such as the Bronx Blood Research Fund (BBRF) provides a platform for research and management of thalassemia and other hemoglobinopathies.

Gene therapy has emerged as a promising treatment option for managing hemoglobin disorder as it targets the underlying genetic cause of the condition through the administration of one-time gene therapy and significantly reduces the need for blood transfusions. The current pipeline of gene therapy products includes CTX001 (CRISPR Therapeutics), BIVV003 (Sangamo Therapeutics, Inc. & Bioverativ Inc), and HGB-206 (bluebird bio, Inc).

Regional Insights

North America held the largest revenue share of 40.2% in 2022 owing to increasing awareness of hemoglobinopathies among people and improving healthcare facilities. Various organizations spread awareness by conducting different programs. For instance, the Sickle Cell Disease Coalition creates awareness, funds research programs, and provides access to treatment in the U.S. Its membership includes research, public health, and provider organizations, faith-based organizations, industry representatives, foundations, patient groups, and federal agencies. Various initiatives undertaken by research organizations and government bodies to promote research to develop novel therapies for treating hemoglobinopathies are likely to contribute to the market growth in the region.

Moreover, increasing immigration to North America and Europe from high prevalence areas and improving diagnosis and treatment for common and rare genetic diseases, such as thalassemia and sickle cell disease, are some of the factors expected to fuel the market growth in these regions. The prevalence of hemoglobinopathies among migrated people in North America and Europe is high as compared to native people.

Asia Pacific is estimated to exhibit a lucrative growth rate over the forecast period. The presence of a large number of patients suffering from sickle cell disease and thalassemia is expected to propel market growth in the coming years. Favorable government initiatives, which are aimed at improving the standard of care provided to patients affected with hemoglobinopathies, are contributing to the market growth in the region. Due to improved healthcare facilities, the burden of SCD and thalassemia is growing in the region.

Some of the prominent players in the Hemoglobinopathies Market include:

• Sangamo Therapeutics, Inc.
• Global Blood Therapeutics, Inc.
• bluebird bio, Inc.
• Emmaus Life Sciences Inc.
• Pfizer, Inc.
• Novartis AG
• Prolong Pharmaceuticals, LLC
• Bioverativ Inc.
• Gamida Cell

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global Hemoglobinopathies market.

• Type
  • Thalassemia
  • Sickle Cell Disease
  • Other Hemoglobin (Hb) Variants
• Diagnosis
  • Thalassemia
    • Blood Test
    • Genetic Test
    • Prenatal Genetic Test
    • Pre-implantation Genetic Diagnosis
    • Electrophoresis
    • Others
  • Sickle Cell Disease
    • Blood Test
    • Genetic Test
    • Prenatal Genetic Test
    • Electrophoresis
    • Others
  • Other Hemoglobin (Hb) Variants
    • Blood Test
    • Genetic Test
    • Prenatal Genetic Test
    • Electrophoresis
    • Others
• Therapy
  • Thalassemia
    • Blood Transfusion
    • Iron Chelation Therapy
    • Bone Marrow Transplant
    • Others
  • Sickle Cell Disease
    • Blood Transfusion
    • Hydroxyurea
    • Bone Marrow Transplant
    • Others
  • Other Hemoglobin (Hb) Variants
    • Blood Transfusion
    • Hydroxyurea
    • Iron Chelation Therapy
    • Bone Marrow Transplant
    • Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Full Report is Ready | For Purchase Inquiry@ https://www.novaoneadvisor.com/report/checkout/7658

You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com| +1 9197 992 333

Blog: https://www.novaoneadvisor.com/

Blog: https://www.visionresearchreports.com/

Blog: https://qyresearchmedical.com/